IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 53.351
AS - Asia 7.067
EU - Europa 5.357
SA - Sud America 1.177
AF - Africa 70
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 27
Totale 67.086
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 53.198
SG - Singapore 3.414
CN - Cina 1.674
BR - Brasile 1.001
UA - Ucraina 969
HK - Hong Kong 797
IE - Irlanda 766
DE - Germania 662
IT - Italia 608
KR - Corea 551
PL - Polonia 422
RU - Federazione Russa 416
FR - Francia 378
GB - Regno Unito 364
FI - Finlandia 307
SE - Svezia 201
VN - Vietnam 197
CA - Canada 87
NL - Olanda 87
IN - India 64
ID - Indonesia 63
JP - Giappone 59
AR - Argentina 56
MX - Messico 41
ES - Italia 35
AT - Austria 34
IQ - Iraq 34
BD - Bangladesh 33
EC - Ecuador 26
AU - Australia 25
BE - Belgio 24
CO - Colombia 24
CL - Cile 23
TR - Turchia 22
UZ - Uzbekistan 19
MY - Malesia 18
ZA - Sudafrica 18
PK - Pakistan 17
A2 - ???statistics.table.value.countryCode.A2??? 15
IL - Israele 15
MA - Marocco 15
PE - Perù 15
PY - Paraguay 13
EG - Egitto 12
EU - Europa 12
NZ - Nuova Zelanda 12
GR - Grecia 11
PT - Portogallo 11
SA - Arabia Saudita 11
IR - Iran 9
PH - Filippine 9
VE - Venezuela 9
CH - Svizzera 8
JO - Giordania 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
KE - Kenya 7
AZ - Azerbaigian 6
RO - Romania 6
BO - Bolivia 5
CR - Costa Rica 5
LT - Lituania 5
MK - Macedonia 5
NO - Norvegia 5
NP - Nepal 5
PA - Panama 5
TW - Taiwan 5
AL - Albania 4
DK - Danimarca 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
KZ - Kazakistan 4
TN - Tunisia 4
UY - Uruguay 4
AM - Armenia 3
BG - Bulgaria 3
EE - Estonia 3
GT - Guatemala 3
KH - Cambogia 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BW - Botswana 2
DM - Dominica 2
DO - Repubblica Dominicana 2
GE - Georgia 2
MD - Moldavia 2
OM - Oman 2
SY - Repubblica araba siriana 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
GA - Gabon 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
Totale 67.077
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.542
Houston 12.261
Fairfield 2.728
Ann Arbor 1.724
Singapore 1.487
Ashburn 1.347
Seattle 1.150
Chandler 910
Cambridge 888
Jacksonville 832
Hong Kong 792
Dublin 686
Beijing 592
Medford 531
Dearborn 461
Hangzhou 422
Kraków 403
Santa Clara 304
New York 243
Lawrence 238
Los Angeles 191
The Dalles 166
Zhengzhou 164
Rome 154
San Diego 135
Buffalo 134
Menlo Park 120
Council Bluffs 108
Dallas 103
Helsinki 101
Ho Chi Minh City 84
Mülheim 83
São Paulo 79
Chicago 73
Moscow 68
Milan 60
Redwood City 57
Norwalk 55
London 47
Colorado Springs 46
Mountain View 46
Redondo Beach 45
Cardiff 44
Hanoi 44
Boardman 42
Naples 42
Shanghai 41
Detroit 39
Guangzhou 39
Jakarta 38
San Mateo 37
San Jose 34
Toronto 34
Verona 34
Hefei 33
Nanjing 32
Columbus 31
University Park 31
Rio de Janeiro 30
Palo Alto 28
Belo Horizonte 27
Falls Church 27
Nuremberg 27
Tokyo 27
Kunming 26
Munich 25
Phoenix 25
Brussels 23
Jinan 22
Montreal 22
Saint Petersburg 22
San Francisco 22
Brooklyn 19
Denver 19
Stockholm 18
Brasília 17
Orem 17
Redmond 17
Tashkent 15
Warsaw 15
Chengdu 14
Mexico City 14
Poplar 14
Salvador 14
Curitiba 13
Cangzhou 12
Elk Grove Village 12
Guarulhos 12
Hounslow 12
Lappeenranta 12
Seoul 12
Wuhan 12
Boston 11
Goiânia 11
Shenyang 11
Bogotá 10
Harderwijk 10
Kilburn 10
La Veta 10
Totale 56.754
Salva come PNG Salva come JPEG
Nome #
An update on the pharmacotherapeutic management of lower respiratory tract infections 510
A systems medicine clinical platform for understanding and managing non- communicable diseases 492
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 489
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 487
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 483
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 479
Interaction between corticosteroids and muscarinic antagonists in human airways 473
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 471
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 465
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 463
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 461
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 461
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 460
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 460
β2-Agonist Therapy in Lung Disease 459
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 459
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 456
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 455
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 453
Airflow obstruction: Is it asthma or is it COPD? 447
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 445
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 445
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 444
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 443
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 442
Optimizing drug delivery in COPD: The role of inhaler devices 440
Asthma and comorbid medical illness. 436
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 433
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 433
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 430
Tiotropium formulations and safety: a network meta-analysis 430
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 429
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 429
Umeclidinium for the treatment of chronic obstructive pulmonary disease 425
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 422
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 421
Metabolic syndrome and risk of pulmonary involvement 421
Bronchodilator therapy for chronic cough 420
Role of muscarinic antagonists in asthma therapy 419
Asthma and comorbid medical illness 418
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 417
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 416
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 413
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 412
New Treatments for COPD in the Elderly 410
The Challenges of Precision Medicine in COPD 410
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 409
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 408
The effect of indacaterol during an acute exacerbation of COPD 408
The prevalence of asthma and COPD in Italy: a practice-based study 407
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 406
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 406
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 404
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 401
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 401
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 401
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 401
Translational study searching for synergy between glycopyrronium and indacaterol 401
Biomarkers of lung damage associated with tobacco smoke in induced sputum 401
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 400
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 398
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 398
Comorbidities of asthma 397
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 397
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 397
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 396
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 396
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 395
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 394
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 393
Influence of ethnicity on response to asthma drugs 390
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 387
Indacaterol for the treatment of chronic obstructive pulmonary disease 386
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 385
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 383
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 381
Adherence to COPD treatment: Myth and reality 378
Treating systemic effects of COPD 377
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 376
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 376
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 374
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 369
Cardiovascular disease in patients with COPD 368
The clinical use of regenerative therapy in COPD 366
Diabetes mellitus among outpatients with COPD attending a university hospital. 363
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 359
Biomarkers in COPD 356
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 355
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 354
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 353
COPD diagnosis by a gas sensor array 352
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 352
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 350
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 348
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma 344
Dual bronchodilation and exacerbations of COPD 344
An update on bronchodilators in Phase I and II clinical trials 343
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease 343
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 343
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 340
Totale 40.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.091
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.091
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.181 0 0 0 0 0 830 1.237 831 314 297 485 187
2021/20222.318 153 225 72 55 77 259 145 109 133 271 159 660
2022/20232.677 348 150 54 319 239 662 248 172 235 19 161 70
2023/2024889 192 27 68 11 85 212 61 38 16 34 12 133
2024/20255.845 217 1.349 622 318 184 206 510 321 538 548 565 467
2025/20264.205 649 503 1.208 739 889 217 0 0 0 0 0 0
Totale 67.747